Table 1.
Cases of ESRD attributable to AAV identified in the USRDS
| Physician‐diagnosed AAV (n = 85) | |
|---|---|
| Age, mean (SD), y | 61.3 (17.3) |
| Male sex, n (%) | 47 (55.3) |
| Race, n (%) | |
| White | 81 (95.3) |
| ANCA type, n (%) | 84 (98.8) |
| MPO/P‐ANCA+ | 47 (55.3) |
| PR3/C‐ANCA+ | 33 (38.8) |
| Clinical phenotype, n (%) | |
| MPA | 26 (30.6) |
| GPA | 58 (68.2) |
| Renal limited | 18 (21.2) |
| Renal biopsy, n (%) | 36 (42.4) |
| Pauci‐immune glomerulonephritis | 16 (44) |
| Years from AAV diagnosis to ESRD, median (IQR) | 1 (0‐6) |
| Principal diagnosis code (ICD‐9/ICD‐10), n (%) | |
| GPA (446.4 or M31.31) | 81 (95.3) |
Abbreviations: AAV, antineutrophil cytoplasmic antibody–associated vasculitis; ANCA, antineutrophil cytoplasmic antibody; C‐ANCA, diffuse cytoplasmic ANCA; ESRD, end‐stage renal disease; GPA, granulomatosis with polyangiitis; ICD‐9, International Classification of Diseases, Ninth Revision; ICD‐10, International Classification of Diseases, 10th Revision; IQR, interquartile range; MPA, microscopic polyangiitis; MPO, myeloperoxidase; P‐ANCA, perinuclear ANCA; PR3, peroxidase 3; USRDS, US Renal Data System.